[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-acute-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-acute-pancreatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100053926","thoracic-epidural-block-for-severe-acute-pancreatitis-100053926",false,"NCT07697690","Thoracic Epidural Block for Severe Acute Pancreatitis","Thoracic Epidural Block in Patients With Severe Acute Pancreatitis: A Single-Center, Prospective, Randomized, Open-Label, Parallel-Group Trial","TEB-SAP","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Diagnosis of acute pancreatitis, defined by at least two of the following three criteria: typical acute upper abdominal pain; serum amylase and\u002For lipase greater than three times the upper limit of normal; imaging findings consistent with acute pancreatitis on contrast-enhanced CT, MRI, or ultrasound.\n3. Admission or transfer to the study hospital within 72 hours after symptom onset.\n4. Severe acute pancreatitis, or moderately severe acute pancreatitis with early respiratory, cardiovascular, or renal organ dysfunction.\n5. Expected need for hospitalization and continuous clinical observation for at least 72 hours.\n6. Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Acute exacerbation of chronic pancreatitis.\n2. Acute pancreatitis associated with pancreatic tumor.\n3. Pregnancy or lactation.\n4. Prior percutaneous abdominal drainage, retroperitoneal drainage, endoscopic drainage, necrosectomy, or surgery before randomization that may substantially affect outcome assessment.\n5. End-stage malignant disease or expected survival less than 3 months.\n6. Severe pre-existing cardiac, pulmonary, hepatic, renal, hematologic, immune, or neurological disease judged by investigators to interfere with outcome assessment.\n7. Severe pre-existing neurological disease that prevents assessment of neurological complications.\n8. Coagulopathy or bleeding risk judged to contraindicate epidural catheterization, including severe thrombocytopenia, elevated INR, prolonged APTT, or other clinically significant coagulation abnormality.\n9. Ongoing anticoagulant or antiplatelet therapy for which discontinuation does not meet neuraxial anesthesia safety requirements.\n10. Puncture site infection, epidural abscess, central nervous system infection, or uncontrolled severe systemic infection.\n11. Severe spinal deformity, prior relevant spinal surgery, or anatomical abnormality that prevents safe thoracic epidural catheterization.\n12. Intracranial hypertension, spinal cord disease, radiculopathy, or other central nervous system disorder that contraindicates neuraxial block.\n13. Known allergy to local anesthetics or other study-related medications.\n14. Refractory shock or severe hemodynamic instability not suitable for thoracic epidural block.\n15. Severe psychiatric disease, cognitive impairment, or inability to cooperate with the study without availability of a legally authorized representative.\n16. Participation in another interventional clinical trial within the previous 3 months.\n17. Any other condition that, in the opinion of the investigators, makes the participant unsuitable for enrollment.","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","Severe acute pancreatitis is a serious illness that can cause severe abdominal pain, inflammation, increased abdominal pressure, feeding intolerance, and early problems with breathing, circulation, and kidney function. Patients with severe acute pancreatitis often need treatment in the intensive care unit. Pain control is an important part of treatment, but conventional pain medicines, especially opioids, may cause side effects such as respiratory depression, reduced bowel movement, nausea, vomiting, delirium, and delayed enteral nutrition.\n\nThoracic epidural block is a regional pain-control technique. It may relieve abdominal pain by blocking pain signals and sympathetic nerve activity from the chest and upper abdominal region. This treatment may also reduce the need for systemic opioid medicines, improve bowel function, improve tolerance to enteral nutrition, and reduce the need for early organ support in some patients.\n\nThis study is a single-center, prospective, randomized, open-label, parallel-group trial. Adult patients with severe acute pancreatitis will be randomly assigned to either a thoracic epidural block group or a conventional analgesia group. Patients in the thoracic epidural block group will receive continuous thoracic epidural infusion of ropivacaine alone, without epidural opioids such as sufentanil, fentanyl, or morphine. Intravenous pain medicines will be used only before epidural block initiation, as rescue analgesia when epidural pain control is inadequate, or after epidural block is paused, fails, or is discontinued. Patients in the conventional analgesia group will receive standard pain treatment according to clinical practice.\n\nThe main goal of this study is to determine whether thoracic epidural block can increase the number of days patients are alive and free from ICU-level organ support during the first 14 days after randomization. ICU-level organ support includes invasive mechanical ventilation, noninvasive ventilation, vasoactive or inotropic drug infusion, and renal replacement therapy. The study will also evaluate pain scores, opioid consumption, enteral nutrition tolerance, intra-abdominal pressure, organ function scores, complications, length of ICU and hospital stay, hospital cost, 28-day mortality, and adverse events related to thoracic epidural block.",[28,29,30],"Severe Acute Pancreatitis","Organ Dysfunction","Organ Support",[32,33,34,35,36],"Severe acute pancreatitis","Thoracic epidural block","Ropivacaine","Organ support-free days","Opioid consumption","NOT_YET_RECRUITING","2026-07-07",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":22},"2026-08-01",{"date":45,"type":22},"2028-09-01",{"name":47,"class":48},"First People's Hospital of Chenzhou","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100582731","bowel-sound-in-predicting-the-severity-of-acute-pancreatitis-protocol-of-a-prospective-multi-center-study-100582731","NCT06867120","Bowel Sound in Predicting the Severity of Acute Pancreatitis: Protocol of a Prospective, Multi-center Study","Inclusion criteria:\n\n1. Aged between 18 and 85 years old.\n2. Meet the diagnostic criteria for AP, at least two of the following three: (a) characteristic abdominal pain; (b) serum amylase and lipase levels are greater than three times the upper limit of normal; (c) abdominal images with typical manifestations of AP.\n3. AP patients within 48 hours of onset.\n4. The patient or family members understand the study protocol and sign the informed consent form.\n\nExclusion criteria:\n\nThe patients who fulfill any of the following criteria will be excluded:\n\n1. Patients with serious conditions requiring surgery and abdominal lavage.\n2. Pregnant women.\n3. The patients with muscle and nerve disorders, chronic pancreatitis, inflammatory bowel disease, cancer, and irritable bowel syndrome.\n4. The patients with severe digestive, respiratory, cardiovascular, hematological, endocrine, psychiatric, and infectious diseases.\n5. The patients have a history of abdominal surgery (except appendectomy or cholecystectomy).\n6. Allergic to silicone, polycarbonate materials or medical plaster. The intake of antibiotic, probiotics, and Chinese herbal medicine will be recorded before the collection of the swabs and will not be considered as exclusion criteria.","85 Years",{"count":57,"type":22},352,"1 Month","OBSERVATIONAL","Introduction: Acute pancreatitis (AP) is a common condition, with 20% of cases progressing to severe acute pancreatitis (SAP), which is associated with a poor prognosis. Early identification of patients likely to progress to SAP is crucial for timely intervention. This study aims to use bowel sound monitoring to predict early progression to SAP in AP patients.\n\nMethods and analysis: This study is a prospective, multi-center prognostic study . Investigators will consecutively recruit newly diagnosed acute pancreatitis (AP) patients at emergency departments across three centers from December 2023. Upon enrollment, each patient will undergo continuous bowel sound monitoring for at least 48 hours using standardized equipment and procedures. The primary outcome is the occurrence of SAP during hospitalization. Collected bowel sound data will be analyzed by an unsupervised automated algorithm to estimate a bowel sound activity index, which serves as the main diagnostic indicator for SAP. This process will be fully blinded to patients' SAP status. Investigators will calculate the ROC curve and area under the curve (AUC) for the bowel sound activity index's ability to diagnose SAP. Additionally, this study will perform exploratory analyses on differences in gut microbiota and serum intestinal permeability markers (diamine oxidase, D-lactic acid, and bacterial endotoxin) between patients with and without SAP. Investigators will also assess whether bowel sound monitoring can reflect these inter-group differences.\n\nStrengths and limitations of the study:\n\n1. Our research aims to monitor bowel sounds in real-time and dynamically, providing an objective tool for monitoring intestinal activity in AP patients.\n2. Our research might offer an objective tool to evaluate bowel sounds, aiding in assessing AP patients' intestinal function and complementing existing score systems like the modified Marshall score.\n3. By detecting bowel sounds in the early stage of AP, investigators could better monitor intestinal function, which might aid in predicting the prognosis of AP patients.\n4. Our monitoring system's main limitation is its difficulty in pinpointing bowel sound changes in specific intestinal segments due to its detection across the entire abdomen.",[62,28],"Acute Pancreatitis (AP)",[64,65,66,67],"bowel sound","acute pancreatitis","intestinal function","prediction","RECRUITING","2026-04-02",{"date":71,"type":41},"2026-04-06",{"date":73,"type":41},"2024-04-01",{"date":75,"type":22},"2027-12-31",{"name":77,"class":48},"Peking Union Medical College Hospital",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100604768","fecal-microbiota-transplantation-fmt-in-patients-with-moderate-to-severe-acute-pancreatitis-100604768","NCT07153809","Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis","Randomized, Double-blind Clinical Trial on the Efficacy and Safety of Gut Microbiota Transplantation (FMT) in the Treatment of Moderate to Severe Acute Pancreatitis","Inclusion Criteria:\n\nAge: 18-70 years old Diagnosis: Meets the diagnostic criteria for severe acute pancreatitis (SAP)\n\n* Organ function: There may be organ failure and systemic complications that can be recovered within 48 hours\n* Stage of the disease: Approximately 2 weeks after onset (non acute phase), accompanied by accumulation of pancreatic fluid volume, and significant improvement in CTSI score compared to before (grade II)\n* Nutritional support: Enteral nutrition tube has been left in place Feasibility of transplantation: No absolute contraindications for gut microbiota transplantation\n* Informed Consent: Voluntarily sign a written informed consent form\n* Gastrointestinal status:\n\nAbdominal pressure (bladder pressure measurement)\\\u003C12mmHg ◦ Existence of spontaneous defecation\u002Fexhaust Significant improvement in abdominal distension compared to before\n\nExclusion Criteria:\n\nSerious complications: combined gastrointestinal bleeding or intestinal fistula\n\n* Special population: Pregnant or lactating women\n* Informed refusal: Failure to sign informed consent form\n* Basic organ dysfunction: Prior to admission, there were chronic organ dysfunction in the heart, lungs, liver, kidneys, or blood system Malignant tumor: Suffering from incurable malignant tumors\n* Immune abnormalities:\n\nAutoimmune diseases\n\n◦ Immunosuppression status (solid organ\u002Fbone marrow transplantation history, AIDS, long-term use of immunosuppressants\u002Fhormones)\n\n* Enteral nutrition intolerance: unable to meet 50% of calorie requirements due to severe diarrhea, fibrotic intestinal stenosis, severe gastrointestinal edema, high flow intestinal fistula, etc\n* Systemic infection: meets the diagnostic criteria for systemic inflammatory response syndrome (SIRS)\n* Antibiotic dependence: broad-spectrum antibiotic intervention is required for combined extraintestinal organ infections\n* Immunodeficiency: Congenital or acquired immunodeficiency\n* Mental illness: severe mental disorders","70 Years",{"count":88,"type":22},80,[25],"This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.",[92,28],"Acute Pancreatitis","2025-08-31",{"date":95,"type":41},"2025-09-04",{"date":97,"type":41},"2024-10-12",{"date":99,"type":22},"2026-12-31",{"name":101,"class":48},"Changhai Hospital",2]